Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2017-04-20 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a detailed correspondence letter from Novartis AG to the SEC regarding their Form 20-F for the fiscal year ended December 31, 2016. It addresses SEC comments and provides detailed responses about various disclosures, including contacts with sanctioned countries, materiality of those contacts, and impairment assessments related to goodwill and intangible assets. The letter references the 2016 Form 20-F and excerpts from the Annual Report 2016, indicating it is a regulatory response related to the annual report filing. The content is not the annual report itself but a letter responding to SEC comments on that report. The document is lengthy (15,000 characters) and contains substantive discussion but is primarily a regulatory correspondence. According to the rules, such correspondence related to SEC comment letters on annual reports is best classified as Regulatory Filings (RNS), as it does not contain the full annual report or financial statements but is a regulatory communication about the report.
2017-04-20 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to SEC rules. It announces the FDA's acceptance of a Biologics License Application (BLA) for a CAR-T cell therapy and the granting of priority review. The content is primarily a press release about regulatory and clinical progress, not a financial report or detailed financial data. The document length is about 13,289 characters, which is substantial but the content is an announcement rather than a full report. There is no detailed financial performance data, no earnings figures, no management discussion of financial results, nor is it a transcript or governance document. It is not an annual or interim report, nor an earnings release. It is a regulatory announcement about a product approval process and clinical trial results. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2017-03-30 English
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a letter from Novartis AG addressed to the SEC regarding their Form 20-F for the fiscal year ended December 31, 2016. It references a prior filing (Form 20-F) and a letter from the SEC, indicating it is correspondence related to regulatory review or inquiry. The document length is short (1087 characters) and it does not contain financial statements or detailed financial data itself. It is a regulatory correspondence rather than the actual annual report or financial filing. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements, compliance documents, and correspondence with regulators that do not fit other categories.
2017-03-27 English
Regulatory Filings 2017
Regulatory Filings
2017-03-23 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It provides an update on the Phase III RELAX-AHF-2 study results, which is a clinical trial outcome announcement. The document is not a full annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory filing providing material information about clinical trial results and company updates. The document length is about 13,931 characters, which is consistent with a detailed regulatory announcement rather than a brief press release or a full financial report. There is no indication that this is a certification or a proxy statement, nor does it fit into categories like M&A, capital update, or director dealings. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2017-03-22 English
FORM 4 SUBMISSION
Director's Dealing
2017-03-18 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.